What's driving the In-vitro Diagnostics Market trends? Abbott, Johnson & Johnson, Siemens, Becton Dickinson, BioRad, Luminex, Thermo Fisher Scientific, LivaNova, BioMerieux, Cephied, Danaher, Roche Diagnostics, Grifols, Qiagen

Market Study Report LLC adds new research on In-vitro Diagnostics market, which is a detailed analysis of this business space inclusive of the trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application potential, and the regional growth landscape, In-vitro Diagnostics market also includes an in-depth study of the industry competitive scenario.

In-vitro Diagnostics Market will exceed USD 97.2 billion by 2025; as per a new research report.
Increasing number of pathology labs equipped with advanced diagnostics machine will prove beneficial for in-vitro diagnostics market growth in near future.

Request a sample of this premium report at https://www.marketstudyreport.com/request-a-sample/1230579?utm_source=openpr.com&utm_medium=Abhijeet

Some of the notable competitive players engaged in the in-vitro diagnostics market are Becton Dickinson, Abbott, Johnson & Johnson, BioRad, Luminex, Thermo Fisher Scientific, LivaNova, BioMerieux, Cephied, Danaher, Roche Diagnostics, Siemens, Grifols, and Qiagen.

These industry players implement several strategies such as mergers, acquisitions, collaborations, product launches, geographical expansions and emphasis on R&D activities to sustain competition and capture higher market share. For instance, in May 2018, LivaNova received CE Mark for Vagus Nerve Stimulation (VNS) Therapy. VNS system comprises of next generation programming system and SenTiva generator for treatment of patients with drug resistant epilepsy. Approval from various regulatory authority bodies will enable company to have competitive edge over its peers.

Now a days, pathology labs are incorporating latest technology instruments to provide superior quality services to patients. Moreover, advanced technology enables in detection of several diseases before their onset. This in turn enhances overall clinical outcome that will prevent further complications. As a result, growing number of laboratories incorporating technologically advanced machines will augment in-vitro diagnostics market growth over the forecast period.

Rising preference towards personalized medicines for treatment of several chronic diseases will accelerate demand for in-vitro diagnostics in forthcoming future. Advantages of personalized medicines such as optimum dosage delivery, target and accurate treatment will rise preference towards it. Thus, demand for IVD will substantially grow to develop new therapies for treating chronic disorders. However, high cost of in-vitro diagnostic services may hinder market growth to certain extent.

Services segment of in-vitro diagnostics market was valued around USD 47 billion in 2018 and it is anticipated to grow significantly over the forecast period. Surging requirement for software in diagnostic testing services by healthcare professionals to screen chronic disorders will boost segment growth over the forecast period. Additionally, rising utilization of currently developed software to manage patients data will enable accurate diagnosis thereby, fueling segment growth.

Molecular diagnostics segment is anticipated to witness more than 7% CAGR over the analysis timeframe. Substantial growth can be attributed to increasing demand for superior quality diagnostics for detecting rare and chronic conditions. Molecular diagnostics provide accurate, sensitive results and has quick turnaround time that enhances overall clinical outcomes. Furthermore, growing disease burden across the globe will influence demand for molecular diagnostics thereby, augmenting segment growth in near future.

Diabetes segment held around USD 10 billion revenue in 2018 and it will grow enormously over the analysis timeframe. Diabetes is one of the major risk factors for kidney failure, blindness, strokes, heart attacks and amputation of lower limbs. Thus, government and industry players are undertaking several initiatives such as conducting campaigns to make people aware regarding benefits of early diagnosis. Thus, increasing awareness amongst people and rising cases of diabetes will surge demand for in-vitro diagnostics in forthcoming future.

Academic institutes segment of IVD market is anticipated to witness more than 6% growth over the analysis timeframe. Increasing research and development activities for developing better quality drugs for diseases such as TB, malaria, HIV, HPV, hepatitis and syphilis infections will escalate demand for IVD. Moreover, extended use of in-vitro diagnostics in the process of drug discovery has augmented its demand in academic institutes that will boost segment growth in near future.

Europe in-vitro diagnostics market held more than 20% revenue share in 2018 and it is anticipated to witness significant growth in forthcoming future. Increasing number of baby boomers in the region will augment demand for in-vitro diagnostics for detection of various ailments. Also, availability of technologically advanced instruments such as clinical chemistry, blood gas analysis, etc for accurate diagnosis will favor regional growth over the analysis timeframe.

Request a discount on standard prices of this premium report at https://www.marketstudyreport.com/check-for-discount/1230579?utm_source=openpr.com&utm_medium=Abhijeet

Report Content
Chapter 1. Methodology

Chapter 2. Executive Summary

Chapter 3. In-vitro Diagnostics Industry Insights

Chapter 4. In-vitro Diagnostics Market, By Type

Chapter 5. In-vitro Diagnostics Market, By Technology

Chapter 6. In-vitro Diagnostics Market, By Application

Chapter 7. In-vitro Diagnostics Market, By End-user

Chapter 8. In-vitro Diagnostics Market, By Region

Chapter 9. Company Profiles

9.1. Abbott

9.2. BD

9.3. Bio-Rad Laboratories, Inc.

9.4. bioM�rieux SA

9.5. Cephied (Danaher Corporation)

9.6. Grifols, S.A.

9.7. Johnson & Johnson Services, Inc.

9.8. Luminex

9.9. LivaNova PLC (Sorin)

9.10. Ortho Clinical Diagnostics

9.11. Qiagen

9.12. F. Hoffmann-La Roche Ltd

9.13. Siemens AG

9.14. Sysmex Corporation

9.15. Thermo Fisher Scientific

buying decision on this premium report https://www.marketstudyreport.com/enquiry-before-buying/1230579?utm_source=openpr.com&utm_medium=Abhijeet

Contact Us:

Market Study Report LLC

4 North Main Street,

Selbyville, Delaware 19975

USA

Phone: 1-302-273-0910

US Toll Free: 1-866-764-2150

Email: sales@marketstudyreport.com

Website: https://www.marketstudyreport.com

Blog: https://www.marketstudyreport.com/blog

About Us:

Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.

This release was published on openPR.